Skip to main content Skip to search Skip to main navigation

Switzerland: New MepV and KlinV-Mep adopted

On 1 July 2020, the Swiss Federal Council adopted the revised Ordinance on Medical Devices (MedDO) and the new Ordinance on Clinical Trials for Medical Devices (ClinO-MD).   

These set out the executive measures of the Swiss Therapeutic Products Act and the Swiss Human Research Act approved in 2019. Since 2001, these laws have been based on the provisions of the European Union.  
As the European Medical Devices Regulation (MDR) will now only come into force on 26 May 2021 due to the COVID-19 pandemic, Switzerland is adapting its legislation gradually. Only the regulations deviating therefrom concerning the placing on the market and commissioning of medical devices that have not been subject to a conformity assessment procedure will come into force on 1 August 2020.  
The requirements of the European Regulation on In Vitro Diagnostic Medical Devices (IVDR), which comes into force on 26 May 2022, will be incorporated into a separate regulation. This will be assessed in summer 2021.  
In addition to these projects, the agreement between Switzerland and the EU on the mutual recognition of conformity assessments (MRA) will also be updated. 


Quelle:

Swissmedic: Federal Council approves new MedDO and ClinO-MD 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
What Types of Impurities may be Present in Active Substances?

What Types of Impurities may be Present in Active Substances?


Read more
There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

In pharmaceutical manufacturing, clean air is not a subjective perception but a precisely controlled technical condition that is essential for product safety. Heating, ventilation and air-conditioning (HVAC) systems ensure, through airflow management, air filtration and pressure control, that particles and microorganisms are kept away from critical areas. This is based on clearly defined requirements for air changes, cleanliness classes, airflow patterns and pressure concepts, all of which are designed according to the manufacturing process and contamination risk involved.
Read more
Previous
Next